MedTrace Logo

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

NCT05360238 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-07-22

No results posted yet for this study

Summary

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

Conditions

  • Follicular B-cell Non-Hodgkin's Lymphoma
  • Mantle Cell Lymphoma Recurrent
  • Mantle Cell Lymphoma Refractory
  • Small Lymphocytic Lymphoma, Relapsed
  • Waldenstrom's Macroglobulinemia Recurrent
  • Waldenstrom's Macroglobulinemia Refractory
  • Chronic Lymphoid Leukemia in Relapse
  • B-cell Lymphoma Refractory

Interventions

BIOLOGICAL

MB-106

T-cells derived from autologous leukapheresis that are genetically modified.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mustang Bio

    lead INDUSTRY

Principal Investigators

  • Mazyar Shadman, MD · Fred Hutchinson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-24
Primary Completion
2024-04-12
Completion
2024-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05360238 on ClinicalTrials.gov